Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma

By Wong Chi   Loong Herbert   Hui Connie   Lau Cecilia   Hui Edwin   Ma Brigette   Chan Anthony  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1399-1408

Springer Publishing Company

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

By  

Clinical Cancer Drugs, Vol. 3, Iss. 1, 2016-05 ,pp. : 36-62

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

By  

Clinical Cancer Drugs, Vol. 3, Iss. 1, 2016-03 ,pp. : 36-62

Bentham Science Publishers

Access to resources Recommend Favorite

Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?

By  

Current Medicinal Chemistry, Vol. 18, Iss. 36, 2011-12 ,pp. : 5528-5544

Bentham Science Publishers

Access to resources Recommend Favorite

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 237-249

Bentham Science Publishers

Access to resources Recommend Favorite